Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a
predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines …

Type 2 helper T cell (Th2)-mediated inflammation plays a critical role in the pathogenesis of
allergic asthma and atopic dermatitis (AD). Recent research focusing on the suppression of …

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a
complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier …

Atopic dermatitis (AD) is a chronic, prevalent, multi-factorial condition that affects infants,
children, and adults. Beyond topical therapy, a variety of systemic agents such as steroids …

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease which predominately
affects children and usually clears up during infancy or childhood. However, AD may persist …

Objective Atopic dermatitis (AD) is an increasingly common inflammatory skin disease
undergoing significant revolution in recent years. New data on disease pathogenesis …

Background Several clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-
13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis …

Recent evidence suggests that interleukin (IL)-13 is a crucial cytokine involved in the
pathogenesis of atopic dermatitis (AD). It is a central driver of type-2 T-helper inflammation …

Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …

Dupilumab, a monoclonal antibody against the common receptor of interleukin (IL)-4 and IL-
13, was the first biologic therapy approved in Canada for treatment of moderate-to-severe …